Multimodality therapy for adenocarcinoma of the esophagus, gastric cardia, and upper gastric third

Recent Results in Cancer Research

Volumn 182, Issue , 2010, Pages 155-166

  Reynolds, John V ^a   Murphy, Thomas J ^a   Ravi, Narayamasamy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; PACLITAXEL; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; CARDIA; ESOPHAGEAL NEOPLASMS; EVIDENCE BASED PRACTICE; STOMACH NEOPLASMS;

ADENOCARCINOMA; CARDIA; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; EVIDENCE-BASED PRACTICE; HUMANS; STOMACH NEOPLASMS;

EID: 77956025651     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-70579-6_13     Document Type: Review

References (40)

1. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TAet al. (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128-1137
2. Blot WJ, De Vesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 265: 1287-1289
3. Bosset J-F, Gignoux M, Tiboulet J-Pet al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337:161-167
4. Burmeister BH, Smithers BM, Gebski V, Fitzgerald Let al. (2005) Surgery alone versus chemoradiotherapy followed by surgery for respectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6:659-668
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Muese M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
7. Cunningham D, Starling N, Rao S, Iveson Tet al. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46
8. Daly JM (2000) Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190:562-572
9. Enzinger PC, Mayer RJ (2003) Esophageal Cancer. N Engl J Med 349:2241-2252
10. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R, Jankowski J (2007) A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 13: 5869-5875
11. Fiorica F, DiBona D, Schepis F, Licata A, Shahied Let al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53:925-930
12. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226-234
13. Geh JI, Crellin AM, Glynne-Jones R (2001) Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 88:338-356
14. Gillham CM, Lucey JA, Keogan M, Duffy GJ,et al. (2006) (18) FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 95: 1174-1179
15. Habr-Gama A, Perez RO, Nadalin W, Sabbago Jet al. (2004) Operative versus nonoperative treatment for Stage 0 distal rectal cancer following chemoradiation therapy. Long term results. Ann Surg 240:711-718
16. Kelsen DP, Ginsberg R, Pajak TFet al. (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1974-1984
17. Kleespies A, Guba M, Jauch KW, Bruns CJ (2004) Vascular endothelial growth factor in esophageal cancer. Surg Oncol 87(2):95-104
18. Lee HK, Vapociyan AA, Cox JD, Tucker SLet al. (2003) Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57:1317-1322
19. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9):797-805
20. Macdonald JS, Smalley SR, Benedetti J, Hundahl SAet al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of stomach or gastroesophageal junction. N Engl J Med 345:725-730
21. Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8: 545-553
22. Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727-1733
23. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 10(24):4692-4698
24. Peters CJ, Fitzgerald RC (2007) Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther 25:1253-1269
25. Portale G, Hagen JA, Peters JH, Chan LSet al. (2006) Modern 5-year survival of respectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 202: 588-596
26. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593-4599
27. Reynolds JV, Ravi N, Hollywood D, Kennedy MJ, Rowley SM, Ryan A, Hughes N, Carey M, Byrne P (2006) Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg 132:549-555
28. Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy MJ, Murphy TJ (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for oesophageal cancer. Ann Surg 245:707-716
29. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, Spector J, Kennedy N, Kennedy T (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391-395
30. Sauer R, Becker H, Hohenberger Wet al. (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740
31. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201-5206
32. Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophago-gastric junction. Br J Surg 85:1457-1459
33. Siewert JR, Feith M, Werner M, Stein HJ (2000) Adenocarcinoma of the esophagastric junction: results of surgical therapy based on anatomical/ topographical classification in 1002 consecutive patients. Ann Surg 232:353-361
34. Suntharalingam M, Mougham J, Coia LRet al. (1999) The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Cancer 85:2499-2505
35. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086-1092
36. Urba SG, Orriner MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Randomised trial of preoperative chemoradiotherapy versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313
37. van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA (2008) A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol 15:88-95
38. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467
39. Wayman J, Bennett MK, Raimes SA, Griffin SM (2002) The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 86(8):1223-1229
40. Weber WA, Ott K, Becker K, Dittler HJet al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065